Introduction
This article serves as a formal correction to a 2018 study published in the Journal of Experimental & Clinical Cancer Research. The primary objective is to rectify a graphical error in Figure 5C (specifically panel 4, the InmiR-26a + silinc01296 group in SW620 cells). Beyond the correction, the data underscores a critical regulatory mechanism involving the LINC01296/miR-26a/GALNT3 axis in colorectal cancer (CRC) progression and chemoresistance.
The Molecular Mechanism: LINC01296/miR-26a/GALNT3
Colorectal cancer remains a significant global health challenge, often exacerbated by metastasis and resistance to standard treatments like 5-Fluorouracil (5-FU). This research identifies the long non-coding RNA (lncRNA) LINC01296 as a master regulator.
Following the "competitive endogenous RNA" (ceRNA) hypothesis, LINC01296 acts as a molecular "sponge," sequestering miR-26a. Under normal conditions, miR-26a suppresses oncogenic targets; however, its sequestration by LINC01296 leads to the overexpression of GALNT3. This enzyme facilitates the O-glycosylation of the MUC1 protein, which in turn activates the PI3K/AKT signaling pathway—a major driver of tumor growth and survival.
Experimental Methodology
The study utilized human CRC cell lines (SW620 and HCT-8) to map this pathway:
- Genetic Manipulation: Researchers employed siRNAs to silence LINC01296 and miRNA mimics or inhibitors to modulate miR-26a levels.
- Phenotypic Characterization: Cell proliferation was assessed via CCK8 and colony formation assays. Migration and invasion were quantified using Transwell assays.
- Biochemical and Drug Sensitivity Analysis: Flow cytometry with VVA lectin detected changes in cell-surface O-linked glycosylation. Additionally, the researchers determined the $IC_{50}$ of 5-FU to evaluate how the LINC01296/miR-26a axis influences chemoresistance.
Key Results
The experimental data, consolidated in the revised Figure 5, demonstrates the profound impact of this axis on cancer cell phenotype.
- Proliferation and Invasion: Inhibiting miR-26a or overexpressing LINC01296 significantly enhanced the colony-forming ability and invasive potential of CRC cells. Silencing LINC01296 was shown to effectively reverse these aggressive traits (Panels B-D, J-L).
- Glycosylation and Signaling: Flow cytometry confirmed that manipulating these factors directly alters O-linked glycosylation levels on the cell surface (Panels A, I), providing a biochemical link to the activation of downstream oncogenic pathways.
- Chemoresistance to 5-FU: In resistant cell lines (HCT-8/5-FU), the axis was shown to modulate drug sensitivity. High levels of LINC01296 correlated with increased survival during 5-FU treatment, while its inhibition sensitized cells to the drug (Panels E-H, M-P).
Conclusion and Future Directions
The LINC01296/miR-26a/GALNT3 axis represents a promising therapeutic target for CRC. While these in vitro results provide a clear mechanistic framework, future research must validate these findings in animal models and clinical cohorts. Overcoming the challenges of delivering RNA-based therapies remains a critical hurdle for translating these insights into effective patient treatments.
Summary updated